Cost: Varies 10
The widespread interest in GLP-1 receptor agonists for weight loss, particularly amid drug shortages, has renewed clinical and regulatory attention to their safety profile, yet the clinical profile of acute exposures remains poorly understood, wrote first author Jordan Miller, a researcher with The University of Texas at San Antonio, and colleagues
Tirzepatide adds GIP receptor agonism for greater potency, and retatrutide adds glucagon agonism for the most advanced metabolic support
Novo and Viatris told a Delaware judge last Wednesday that they had settled Novo's lawsuit against Viatris there over its proposed generic of Ozempic
Both Semaglutide and Tirzepatide are GLP-1 weight loss medications, but Tirzepatide also targets GIP receptors, providing broader effects on insulin and appetite control
Should any of these persist or get worse after a few days, even if its still relatively mild, seek medical attention